2024-10-18 17:43:04,726 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:43:04,727 - INFO - Run 0:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, I will follow a structured approach using the principles of superforecasting and analyze the information provided.

1. **Reference Class Analysis**: Historically, viral outbreaks similar to mpox, such as monkeypox, have been rated as "Very Low" or "Low" risk in the US unless there is significant domestic transmission. The context of mpox being considered a public health emergency in Africa and by the WHO adds an external risk factor, but historically, such declarations have not always altered the domestic risk assessment by the CDC unless there is proven local transmission.

2. **Recent Developments**: The CDC's latest risk assessment for mpox as of August 14, 2024, indicated a "VERY LOW" overall risk for the US general population, with a slightly higher risk for specific groups like gay, bisexual, and other men who have sex with men (MSM). Given that this is the latest available assessment and no significant updates have been reported beyond this date that indicate widespread transmission within the US, this remains a key piece of evidence.

3. **Current Context**: Despite the WHO declaring mpox a global emergency and the risk increase in Africa and even moderate alerts in Europe, there is a lack of evidence indicating widespread outbreaks or transmission within the US, which would typically trigger a higher risk assessment by the CDC. Reports suggest some level of preparedness and vaccine availability in the US, reducing the likelihood of such escalation.

4. **Balancing Evidence and Overreaction**: While the situation in Africa and the international response may suggest an increased global risk perception, this has not yet translated to an increased domestic risk for the US general population. It is essential not to overreact to international developments when the available information indicates that the CDC maintains a "very low" overall risk assessment. Any potential change would require significant domestic transmission or cases that challenge the current risk assessment level.

5. **Extrapolation and Trends**: Given the historical context and the current assessments, a linear extrapolation of past risk assessments to the present suggests no major deviation unless significant local outbreaks occur. The proactive measures and existing vaccine stockpiles in the US add resilience against sudden changes in risk perception.

Based on these analyses, the probability that the CDC will assess the risk posed by mpox to the US general public as exceeding "Moderate" before October 1, 2024, is assessed as low.

My Prediction: Between 5.00% and 10.00%, but 7.00% being the most likely. Probability: 7.00%.

2024-10-18 17:43:23,902 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:43:23,902 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:43:23,902 - INFO - Run 1:
To answer the question of whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, we need to consider the information available and evaluate it against historical context and recent trends. 

1. **Base Rates and Historical Context**: Historically, mpox (formerly known as monkeypox) outbreaks have been concentrated in Central and West Africa, with limited cases outside these regions. Mpox infections outside Africa tend to be sporadic and linked to travel or imported cases rather than widespread community transmission.

2. **Current Situation and News Analysis**: As of August 2024, the Democratic Republic of the Congo and other African countries are experiencing a significant outbreak of a new, more virulent variant of mpox (clade I). The World Health Organization (WHO) has declared mpox a global public health emergency due to the risk of international spread. However, the CDC's latest Rapid Risk Assessment rated the risk to the US general public as VERY LOW, with a low to moderate risk for specific high-risk groups (e.g., MSM with multiple partners).

3. **Epidemiological Considerations**: The current mpox strains pose a greater threat within Africa due to limited vaccination, surveillance, and healthcare infrastructure. In contrast, the US has a strategic vaccine reserve, testing capabilities, and a robust public health infrastructure to manage potential cases.

4. **Logistical and Practical Aspects**: The CDC's decision to revise its risk assessment would likely stem from indicators such as higher numbers of cases detected in the US, evidence of sustained transmission within the community, or changes in virus transmissibility or severity. Currently, there is no evidence suggesting such developments in the US.

5. **Insights from News Articles and Statements**: Several articles and public health statements highlight concerns about the potential for imported cases and the increased transmissibility of the new variant. However, no specific evidence suggests that this has led to a rise in cases within the US to the extent that would necessitate raising the risk level beyond "Moderate."

6. **Triage of Prediction Models**: As of now, platforms such as Metaculus or other forecasting communities might assess the continued low risk given current data. Statements from WHO, ECDC, and other health agencies provide information helpful for understanding global trends but do not directly translate to an increased risk for the US.

7. **Balancing Evidence for a Forecast**: The key balancing act in this forecast is between the potential for global spread due to high transmissibility in Africa and the existing infrastructure and vaccination readily available in the US, which reduces the likelihood of a moderate or higher threat level.

Considering all these factors and historical precedent, I find that the probability that the CDC will upgrade its risk assessment of mpox to above "Moderate" for the general US public by October 1, 2024, remains low. Given the steps being taken to monitor and mitigate risks, the current trajectory seems stable with no immediate shifts in healthcare assessments for the general US public. 

My Prediction: Between 1.00% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-18 17:43:23,902 - INFO - Run 1:
To answer the question of whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, we need to consider the information available and evaluate it against historical context and recent trends. 

1. **Base Rates and Historical Context**: Historically, mpox (formerly known as monkeypox) outbreaks have been concentrated in Central and West Africa, with limited cases outside these regions. Mpox infections outside Africa tend to be sporadic and linked to travel or imported cases rather than widespread community transmission.

2. **Current Situation and News Analysis**: As of August 2024, the Democratic Republic of the Congo and other African countries are experiencing a significant outbreak of a new, more virulent variant of mpox (clade I). The World Health Organization (WHO) has declared mpox a global public health emergency due to the risk of international spread. However, the CDC's latest Rapid Risk Assessment rated the risk to the US general public as VERY LOW, with a low to moderate risk for specific high-risk groups (e.g., MSM with multiple partners).

3. **Epidemiological Considerations**: The current mpox strains pose a greater threat within Africa due to limited vaccination, surveillance, and healthcare infrastructure. In contrast, the US has a strategic vaccine reserve, testing capabilities, and a robust public health infrastructure to manage potential cases.

4. **Logistical and Practical Aspects**: The CDC's decision to revise its risk assessment would likely stem from indicators such as higher numbers of cases detected in the US, evidence of sustained transmission within the community, or changes in virus transmissibility or severity. Currently, there is no evidence suggesting such developments in the US.

5. **Insights from News Articles and Statements**: Several articles and public health statements highlight concerns about the potential for imported cases and the increased transmissibility of the new variant. However, no specific evidence suggests that this has led to a rise in cases within the US to the extent that would necessitate raising the risk level beyond "Moderate."

6. **Triage of Prediction Models**: As of now, platforms such as Metaculus or other forecasting communities might assess the continued low risk given current data. Statements from WHO, ECDC, and other health agencies provide information helpful for understanding global trends but do not directly translate to an increased risk for the US.

7. **Balancing Evidence for a Forecast**: The key balancing act in this forecast is between the potential for global spread due to high transmissibility in Africa and the existing infrastructure and vaccination readily available in the US, which reduces the likelihood of a moderate or higher threat level.

Considering all these factors and historical precedent, I find that the probability that the CDC will upgrade its risk assessment of mpox to above "Moderate" for the general US public by October 1, 2024, remains low. Given the steps being taken to monitor and mitigate risks, the current trajectory seems stable with no immediate shifts in healthcare assessments for the general US public. 

My Prediction: Between 1.00% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-18 17:43:47,331 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:43:47,331 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:43:47,331 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:43:47,331 - INFO - Run 2:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, I will follow a structured, evidence-based approach. 

1. **Base Rates and Comparisons**: 
   - Historically, the CDC has been cautious in raising threat levels. High-level alerts for the general public are rare and usually occur when there are significant domestic outbreaks or when there is a strong likelihood of domestic spread from foreign outbreaks. Past global health threats such as SARS, MERS, and Ebola involved significant international concern; however, the threat level to the US general public often remained low unless direct transmission within the country was confirmed.
   - The recent CDC assessments, up to August 14, 2024, place the risk to the US general population as "VERY LOW," even considering the severity of outbreaks elsewhere.

2. **News Analysis and Evidence**:
   - Current news articles indicate a serious outbreak in Africa with increasing spread to other continents, necessitating alerts from WHO and concerns about global spread.
   - Europe has raised its risk assessment to "moderate" due to imported cases but maintains a "very low" risk for internal spread.
   - The recent CDC assessment (August 14, 2024) still considers the risk to the US population as "VERY LOW," despite the situation in Africa and sporadic global cases.
   - The articles suggest the disease is currently predominantly affecting regions with low resources and high transmission potential within those confined areas.

3. **Risk Factors and Constraints**:
   - Transmission vectors mentioned (including sexual transmission and animal contact) may not significantly impact the general US population due to different social structures and health protocols.
   - US inbound travel from the most affected areas (DRC and neighboring countries) is limited, reducing the likelihood of significant domestic transmission.
   - Existing measures such as vaccines, surveillance, and public health infrastructure reduce the probable impact.

4. **Balancing Evidence and Error**:
   - While global spread is causing concern, WHO and CDC continue to manage risks through measures rather than elevate threat levels unnecessarily.
   - The CDC's historical conservatism in raising public risk levels unless clear evidence necessitates it, coupled with the current situation where neither domestic spread nor significant case clusters warranting an increase from "VERY LOW" to "MODERATE," creates a stable low-risk assessment.

5. **Assessment**:
   - Current evidence heavily supports the status staying below "Moderate" risk given the controlled transmission vectors and lack of domestic threat.
   - No new significant data or trends suggest the conditions that prompted current African outbreaks will analogously affect the US. 

Thus, taking into account all the gathered data, recent trends, and patterns of CDC's and WHO's risk assessments throughout similar situations, the prediction is based on the best risk assessment underlined by recent actions from related agencies.

My Prediction: Between 1.00% and 3.00%, but 2.00% being the most likely. Probability: 2.00%.

2024-10-18 17:43:47,331 - INFO - Run 2:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, I will follow a structured, evidence-based approach. 

1. **Base Rates and Comparisons**: 
   - Historically, the CDC has been cautious in raising threat levels. High-level alerts for the general public are rare and usually occur when there are significant domestic outbreaks or when there is a strong likelihood of domestic spread from foreign outbreaks. Past global health threats such as SARS, MERS, and Ebola involved significant international concern; however, the threat level to the US general public often remained low unless direct transmission within the country was confirmed.
   - The recent CDC assessments, up to August 14, 2024, place the risk to the US general population as "VERY LOW," even considering the severity of outbreaks elsewhere.

2. **News Analysis and Evidence**:
   - Current news articles indicate a serious outbreak in Africa with increasing spread to other continents, necessitating alerts from WHO and concerns about global spread.
   - Europe has raised its risk assessment to "moderate" due to imported cases but maintains a "very low" risk for internal spread.
   - The recent CDC assessment (August 14, 2024) still considers the risk to the US population as "VERY LOW," despite the situation in Africa and sporadic global cases.
   - The articles suggest the disease is currently predominantly affecting regions with low resources and high transmission potential within those confined areas.

3. **Risk Factors and Constraints**:
   - Transmission vectors mentioned (including sexual transmission and animal contact) may not significantly impact the general US population due to different social structures and health protocols.
   - US inbound travel from the most affected areas (DRC and neighboring countries) is limited, reducing the likelihood of significant domestic transmission.
   - Existing measures such as vaccines, surveillance, and public health infrastructure reduce the probable impact.

4. **Balancing Evidence and Error**:
   - While global spread is causing concern, WHO and CDC continue to manage risks through measures rather than elevate threat levels unnecessarily.
   - The CDC's historical conservatism in raising public risk levels unless clear evidence necessitates it, coupled with the current situation where neither domestic spread nor significant case clusters warranting an increase from "VERY LOW" to "MODERATE," creates a stable low-risk assessment.

5. **Assessment**:
   - Current evidence heavily supports the status staying below "Moderate" risk given the controlled transmission vectors and lack of domestic threat.
   - No new significant data or trends suggest the conditions that prompted current African outbreaks will analogously affect the US. 

Thus, taking into account all the gathered data, recent trends, and patterns of CDC's and WHO's risk assessments throughout similar situations, the prediction is based on the best risk assessment underlined by recent actions from related agencies.

My Prediction: Between 1.00% and 3.00%, but 2.00% being the most likely. Probability: 2.00%.

2024-10-18 17:43:47,331 - INFO - Run 2:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, I will follow a structured, evidence-based approach. 

1. **Base Rates and Comparisons**: 
   - Historically, the CDC has been cautious in raising threat levels. High-level alerts for the general public are rare and usually occur when there are significant domestic outbreaks or when there is a strong likelihood of domestic spread from foreign outbreaks. Past global health threats such as SARS, MERS, and Ebola involved significant international concern; however, the threat level to the US general public often remained low unless direct transmission within the country was confirmed.
   - The recent CDC assessments, up to August 14, 2024, place the risk to the US general population as "VERY LOW," even considering the severity of outbreaks elsewhere.

2. **News Analysis and Evidence**:
   - Current news articles indicate a serious outbreak in Africa with increasing spread to other continents, necessitating alerts from WHO and concerns about global spread.
   - Europe has raised its risk assessment to "moderate" due to imported cases but maintains a "very low" risk for internal spread.
   - The recent CDC assessment (August 14, 2024) still considers the risk to the US population as "VERY LOW," despite the situation in Africa and sporadic global cases.
   - The articles suggest the disease is currently predominantly affecting regions with low resources and high transmission potential within those confined areas.

3. **Risk Factors and Constraints**:
   - Transmission vectors mentioned (including sexual transmission and animal contact) may not significantly impact the general US population due to different social structures and health protocols.
   - US inbound travel from the most affected areas (DRC and neighboring countries) is limited, reducing the likelihood of significant domestic transmission.
   - Existing measures such as vaccines, surveillance, and public health infrastructure reduce the probable impact.

4. **Balancing Evidence and Error**:
   - While global spread is causing concern, WHO and CDC continue to manage risks through measures rather than elevate threat levels unnecessarily.
   - The CDC's historical conservatism in raising public risk levels unless clear evidence necessitates it, coupled with the current situation where neither domestic spread nor significant case clusters warranting an increase from "VERY LOW" to "MODERATE," creates a stable low-risk assessment.

5. **Assessment**:
   - Current evidence heavily supports the status staying below "Moderate" risk given the controlled transmission vectors and lack of domestic threat.
   - No new significant data or trends suggest the conditions that prompted current African outbreaks will analogously affect the US. 

Thus, taking into account all the gathered data, recent trends, and patterns of CDC's and WHO's risk assessments throughout similar situations, the prediction is based on the best risk assessment underlined by recent actions from related agencies.

My Prediction: Between 1.00% and 3.00%, but 2.00% being the most likely. Probability: 2.00%.

2024-10-18 17:44:17,772 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:44:17,772 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:44:17,772 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:44:17,772 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:44:17,773 - INFO - Run 3:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, a comprehensive analysis of the current situation and historical trends is necessary.

1. **Base Rate and Historical Context**: Historically, the CDC has been conservative in elevating risk levels for diseases unless there is direct evidence of transmission and substantial risk to the US population. Given the assessment during the initial mpox outbreak in 2022, where risks for the general population remained low, there has been a pattern of cautious elevation of risk levels.

2. **Current Situation**: Mpox has been declared a public health emergency in Africa, with significant outbreaks in the Democratic Republic of Congo. However, reports consistently state that the risk to the US general public remains low due to geographically limited transmission, the nature of transmission, and the relative isolation of the outbreak.

3. **Comparative and Current Assessments**: CDC’s current assessment remains at "VERY LOW" for the general US population, with moderate assessment for subpopulations at higher risk. The CDC’s tendency to remain vigilant rather than reactionary (with bi-weekly updates) indicates they are more likely to update their assessment only if there are substantial changes in transmission dynamics or introduction to the US.

4. **Global and National Response**: The WHO has raised the alert level globally, affecting international responses, but other national bodies have echoed a consensus of continued low risk to the US general population. The infrastructure in place for mpox tracking and response, including vaccinations, also mitigates the risk of escalation.

5. **Reference Classes and Risk Assessment**: Similar cases, such as the Ebola scare, or initial COVID-like scenarios, illustrate the CDC's reserve in raising public risk assessments unless there are significant indicators of rapid spread or domestic introduction. The CDC has previously relied on data-driven evaluations rather than speculative worst-case scenarios.

6. **Judgment and Conclusion**: Considering the current evidence and external assessments, the probability of the CDC's risk assessment exceeding "Moderate" by the deadline is relatively low. While the situation in Africa and related international concerns warrant careful observation, the absence of a direct threat to the US, ongoing risk assessments falling low or very low, and effective monitoring and control capabilities in the US reduce the likelihood of a change exceeding this level. 

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2024-10-18 17:44:17,773 - INFO - Run 3:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, a comprehensive analysis of the current situation and historical trends is necessary.

1. **Base Rate and Historical Context**: Historically, the CDC has been conservative in elevating risk levels for diseases unless there is direct evidence of transmission and substantial risk to the US population. Given the assessment during the initial mpox outbreak in 2022, where risks for the general population remained low, there has been a pattern of cautious elevation of risk levels.

2. **Current Situation**: Mpox has been declared a public health emergency in Africa, with significant outbreaks in the Democratic Republic of Congo. However, reports consistently state that the risk to the US general public remains low due to geographically limited transmission, the nature of transmission, and the relative isolation of the outbreak.

3. **Comparative and Current Assessments**: CDC’s current assessment remains at "VERY LOW" for the general US population, with moderate assessment for subpopulations at higher risk. The CDC’s tendency to remain vigilant rather than reactionary (with bi-weekly updates) indicates they are more likely to update their assessment only if there are substantial changes in transmission dynamics or introduction to the US.

4. **Global and National Response**: The WHO has raised the alert level globally, affecting international responses, but other national bodies have echoed a consensus of continued low risk to the US general population. The infrastructure in place for mpox tracking and response, including vaccinations, also mitigates the risk of escalation.

5. **Reference Classes and Risk Assessment**: Similar cases, such as the Ebola scare, or initial COVID-like scenarios, illustrate the CDC's reserve in raising public risk assessments unless there are significant indicators of rapid spread or domestic introduction. The CDC has previously relied on data-driven evaluations rather than speculative worst-case scenarios.

6. **Judgment and Conclusion**: Considering the current evidence and external assessments, the probability of the CDC's risk assessment exceeding "Moderate" by the deadline is relatively low. While the situation in Africa and related international concerns warrant careful observation, the absence of a direct threat to the US, ongoing risk assessments falling low or very low, and effective monitoring and control capabilities in the US reduce the likelihood of a change exceeding this level. 

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2024-10-18 17:44:17,773 - INFO - Run 3:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, a comprehensive analysis of the current situation and historical trends is necessary.

1. **Base Rate and Historical Context**: Historically, the CDC has been conservative in elevating risk levels for diseases unless there is direct evidence of transmission and substantial risk to the US population. Given the assessment during the initial mpox outbreak in 2022, where risks for the general population remained low, there has been a pattern of cautious elevation of risk levels.

2. **Current Situation**: Mpox has been declared a public health emergency in Africa, with significant outbreaks in the Democratic Republic of Congo. However, reports consistently state that the risk to the US general public remains low due to geographically limited transmission, the nature of transmission, and the relative isolation of the outbreak.

3. **Comparative and Current Assessments**: CDC’s current assessment remains at "VERY LOW" for the general US population, with moderate assessment for subpopulations at higher risk. The CDC’s tendency to remain vigilant rather than reactionary (with bi-weekly updates) indicates they are more likely to update their assessment only if there are substantial changes in transmission dynamics or introduction to the US.

4. **Global and National Response**: The WHO has raised the alert level globally, affecting international responses, but other national bodies have echoed a consensus of continued low risk to the US general population. The infrastructure in place for mpox tracking and response, including vaccinations, also mitigates the risk of escalation.

5. **Reference Classes and Risk Assessment**: Similar cases, such as the Ebola scare, or initial COVID-like scenarios, illustrate the CDC's reserve in raising public risk assessments unless there are significant indicators of rapid spread or domestic introduction. The CDC has previously relied on data-driven evaluations rather than speculative worst-case scenarios.

6. **Judgment and Conclusion**: Considering the current evidence and external assessments, the probability of the CDC's risk assessment exceeding "Moderate" by the deadline is relatively low. While the situation in Africa and related international concerns warrant careful observation, the absence of a direct threat to the US, ongoing risk assessments falling low or very low, and effective monitoring and control capabilities in the US reduce the likelihood of a change exceeding this level. 

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2024-10-18 17:44:17,773 - INFO - Run 3:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, a comprehensive analysis of the current situation and historical trends is necessary.

1. **Base Rate and Historical Context**: Historically, the CDC has been conservative in elevating risk levels for diseases unless there is direct evidence of transmission and substantial risk to the US population. Given the assessment during the initial mpox outbreak in 2022, where risks for the general population remained low, there has been a pattern of cautious elevation of risk levels.

2. **Current Situation**: Mpox has been declared a public health emergency in Africa, with significant outbreaks in the Democratic Republic of Congo. However, reports consistently state that the risk to the US general public remains low due to geographically limited transmission, the nature of transmission, and the relative isolation of the outbreak.

3. **Comparative and Current Assessments**: CDC’s current assessment remains at "VERY LOW" for the general US population, with moderate assessment for subpopulations at higher risk. The CDC’s tendency to remain vigilant rather than reactionary (with bi-weekly updates) indicates they are more likely to update their assessment only if there are substantial changes in transmission dynamics or introduction to the US.

4. **Global and National Response**: The WHO has raised the alert level globally, affecting international responses, but other national bodies have echoed a consensus of continued low risk to the US general population. The infrastructure in place for mpox tracking and response, including vaccinations, also mitigates the risk of escalation.

5. **Reference Classes and Risk Assessment**: Similar cases, such as the Ebola scare, or initial COVID-like scenarios, illustrate the CDC's reserve in raising public risk assessments unless there are significant indicators of rapid spread or domestic introduction. The CDC has previously relied on data-driven evaluations rather than speculative worst-case scenarios.

6. **Judgment and Conclusion**: Considering the current evidence and external assessments, the probability of the CDC's risk assessment exceeding "Moderate" by the deadline is relatively low. While the situation in Africa and related international concerns warrant careful observation, the absence of a direct threat to the US, ongoing risk assessments falling low or very low, and effective monitoring and control capabilities in the US reduce the likelihood of a change exceeding this level. 

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2024-10-18 17:44:43,093 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:44:43,093 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:44:43,093 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:44:43,093 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:44:43,093 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Moderate" before October 1, 2024?
2024-10-18 17:44:43,094 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, I will follow a systematic approach using superforecasting principles.

**1. Initial Base Rate and Historical Context**:
- Historically, changes in the CDC risk assessment levels tend to occur when there is a significant increase in the number or severity of cases, or when new variants with higher transmission and severity emerge in or threaten the US.
- The current CDC assessment for the US general public is "Very Low", with moderate confidence. Often, the CDC moves between levels like "Very Low", "Low", "Moderate", etc., based on established criteria and evidence.

**2. Current Situation**:
- Mpox outbreaks are concentrated in Africa, mostly in the Democratic Republic of Congo, with specific international warnings due to the spread of a more virulent variant, clade I.
- As of the latest information, there are increased cases of mpox in Africa, with warnings from WHO and ECDC about potential global spread. However, for now, these have largely been confined to Africa with limited spread outside the continent.

**3. Clashing Causal Forces**:
- **For a higher risk assessment**: The emergence of a new, more contagious variant in Africa, potential underreporting or misdiagnosis of cases in the US, increased international travel, and potential infections spreading from Africa to the US.
- **Against a higher risk assessment**: Limited current spread outside Africa, low transmissibility of mpox among the general population without close skin contact, and existing containment and vaccination measures in place.

**4. Extrapolating Current Trends**:
- Current containment measures in non-African countries, international health agency coordination, and awareness of the new variant make a significant outbreak in the US unlikely in the short term. 

**5. Evidence Evaluation**:
- The CDC's own risk assessment remains "Very Low", and there's no emerging evidence suggesting a significant uptick in actual or risk-assessed US cases.
- The most recent reassessment makes the probability of an increased risk assessment ("Moderate" or higher) low, given no current public advisory matching such concerns.

**6. Error Balancing**:
- Risks include missing an unreported spike or a sudden international escalation. However, given current data, assessment protocols and the absence of significant news indicating immediate changes in CDC reports, the likelihood seems minimal.

**Probability Estimation**:
After weighing the reference classes, current trend extrapolation, and balancing evidence, I estimate:

My Prediction: Between 1.00% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-18 17:44:43,094 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, I will follow a systematic approach using superforecasting principles.

**1. Initial Base Rate and Historical Context**:
- Historically, changes in the CDC risk assessment levels tend to occur when there is a significant increase in the number or severity of cases, or when new variants with higher transmission and severity emerge in or threaten the US.
- The current CDC assessment for the US general public is "Very Low", with moderate confidence. Often, the CDC moves between levels like "Very Low", "Low", "Moderate", etc., based on established criteria and evidence.

**2. Current Situation**:
- Mpox outbreaks are concentrated in Africa, mostly in the Democratic Republic of Congo, with specific international warnings due to the spread of a more virulent variant, clade I.
- As of the latest information, there are increased cases of mpox in Africa, with warnings from WHO and ECDC about potential global spread. However, for now, these have largely been confined to Africa with limited spread outside the continent.

**3. Clashing Causal Forces**:
- **For a higher risk assessment**: The emergence of a new, more contagious variant in Africa, potential underreporting or misdiagnosis of cases in the US, increased international travel, and potential infections spreading from Africa to the US.
- **Against a higher risk assessment**: Limited current spread outside Africa, low transmissibility of mpox among the general population without close skin contact, and existing containment and vaccination measures in place.

**4. Extrapolating Current Trends**:
- Current containment measures in non-African countries, international health agency coordination, and awareness of the new variant make a significant outbreak in the US unlikely in the short term. 

**5. Evidence Evaluation**:
- The CDC's own risk assessment remains "Very Low", and there's no emerging evidence suggesting a significant uptick in actual or risk-assessed US cases.
- The most recent reassessment makes the probability of an increased risk assessment ("Moderate" or higher) low, given no current public advisory matching such concerns.

**6. Error Balancing**:
- Risks include missing an unreported spike or a sudden international escalation. However, given current data, assessment protocols and the absence of significant news indicating immediate changes in CDC reports, the likelihood seems minimal.

**Probability Estimation**:
After weighing the reference classes, current trend extrapolation, and balancing evidence, I estimate:

My Prediction: Between 1.00% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-18 17:44:43,094 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, I will follow a systematic approach using superforecasting principles.

**1. Initial Base Rate and Historical Context**:
- Historically, changes in the CDC risk assessment levels tend to occur when there is a significant increase in the number or severity of cases, or when new variants with higher transmission and severity emerge in or threaten the US.
- The current CDC assessment for the US general public is "Very Low", with moderate confidence. Often, the CDC moves between levels like "Very Low", "Low", "Moderate", etc., based on established criteria and evidence.

**2. Current Situation**:
- Mpox outbreaks are concentrated in Africa, mostly in the Democratic Republic of Congo, with specific international warnings due to the spread of a more virulent variant, clade I.
- As of the latest information, there are increased cases of mpox in Africa, with warnings from WHO and ECDC about potential global spread. However, for now, these have largely been confined to Africa with limited spread outside the continent.

**3. Clashing Causal Forces**:
- **For a higher risk assessment**: The emergence of a new, more contagious variant in Africa, potential underreporting or misdiagnosis of cases in the US, increased international travel, and potential infections spreading from Africa to the US.
- **Against a higher risk assessment**: Limited current spread outside Africa, low transmissibility of mpox among the general population without close skin contact, and existing containment and vaccination measures in place.

**4. Extrapolating Current Trends**:
- Current containment measures in non-African countries, international health agency coordination, and awareness of the new variant make a significant outbreak in the US unlikely in the short term. 

**5. Evidence Evaluation**:
- The CDC's own risk assessment remains "Very Low", and there's no emerging evidence suggesting a significant uptick in actual or risk-assessed US cases.
- The most recent reassessment makes the probability of an increased risk assessment ("Moderate" or higher) low, given no current public advisory matching such concerns.

**6. Error Balancing**:
- Risks include missing an unreported spike or a sudden international escalation. However, given current data, assessment protocols and the absence of significant news indicating immediate changes in CDC reports, the likelihood seems minimal.

**Probability Estimation**:
After weighing the reference classes, current trend extrapolation, and balancing evidence, I estimate:

My Prediction: Between 1.00% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-18 17:44:43,094 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, I will follow a systematic approach using superforecasting principles.

**1. Initial Base Rate and Historical Context**:
- Historically, changes in the CDC risk assessment levels tend to occur when there is a significant increase in the number or severity of cases, or when new variants with higher transmission and severity emerge in or threaten the US.
- The current CDC assessment for the US general public is "Very Low", with moderate confidence. Often, the CDC moves between levels like "Very Low", "Low", "Moderate", etc., based on established criteria and evidence.

**2. Current Situation**:
- Mpox outbreaks are concentrated in Africa, mostly in the Democratic Republic of Congo, with specific international warnings due to the spread of a more virulent variant, clade I.
- As of the latest information, there are increased cases of mpox in Africa, with warnings from WHO and ECDC about potential global spread. However, for now, these have largely been confined to Africa with limited spread outside the continent.

**3. Clashing Causal Forces**:
- **For a higher risk assessment**: The emergence of a new, more contagious variant in Africa, potential underreporting or misdiagnosis of cases in the US, increased international travel, and potential infections spreading from Africa to the US.
- **Against a higher risk assessment**: Limited current spread outside Africa, low transmissibility of mpox among the general population without close skin contact, and existing containment and vaccination measures in place.

**4. Extrapolating Current Trends**:
- Current containment measures in non-African countries, international health agency coordination, and awareness of the new variant make a significant outbreak in the US unlikely in the short term. 

**5. Evidence Evaluation**:
- The CDC's own risk assessment remains "Very Low", and there's no emerging evidence suggesting a significant uptick in actual or risk-assessed US cases.
- The most recent reassessment makes the probability of an increased risk assessment ("Moderate" or higher) low, given no current public advisory matching such concerns.

**6. Error Balancing**:
- Risks include missing an unreported spike or a sudden international escalation. However, given current data, assessment protocols and the absence of significant news indicating immediate changes in CDC reports, the likelihood seems minimal.

**Probability Estimation**:
After weighing the reference classes, current trend extrapolation, and balancing evidence, I estimate:

My Prediction: Between 1.00% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-18 17:44:43,094 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Moderate" before October 1, 2024, I will follow a systematic approach using superforecasting principles.

**1. Initial Base Rate and Historical Context**:
- Historically, changes in the CDC risk assessment levels tend to occur when there is a significant increase in the number or severity of cases, or when new variants with higher transmission and severity emerge in or threaten the US.
- The current CDC assessment for the US general public is "Very Low", with moderate confidence. Often, the CDC moves between levels like "Very Low", "Low", "Moderate", etc., based on established criteria and evidence.

**2. Current Situation**:
- Mpox outbreaks are concentrated in Africa, mostly in the Democratic Republic of Congo, with specific international warnings due to the spread of a more virulent variant, clade I.
- As of the latest information, there are increased cases of mpox in Africa, with warnings from WHO and ECDC about potential global spread. However, for now, these have largely been confined to Africa with limited spread outside the continent.

**3. Clashing Causal Forces**:
- **For a higher risk assessment**: The emergence of a new, more contagious variant in Africa, potential underreporting or misdiagnosis of cases in the US, increased international travel, and potential infections spreading from Africa to the US.
- **Against a higher risk assessment**: Limited current spread outside Africa, low transmissibility of mpox among the general population without close skin contact, and existing containment and vaccination measures in place.

**4. Extrapolating Current Trends**:
- Current containment measures in non-African countries, international health agency coordination, and awareness of the new variant make a significant outbreak in the US unlikely in the short term. 

**5. Evidence Evaluation**:
- The CDC's own risk assessment remains "Very Low", and there's no emerging evidence suggesting a significant uptick in actual or risk-assessed US cases.
- The most recent reassessment makes the probability of an increased risk assessment ("Moderate" or higher) low, given no current public advisory matching such concerns.

**6. Error Balancing**:
- Risks include missing an unreported spike or a sudden international escalation. However, given current data, assessment protocols and the absence of significant news indicating immediate changes in CDC reports, the likelihood seems minimal.

**Probability Estimation**:
After weighing the reference classes, current trend extrapolation, and balancing evidence, I estimate:

My Prediction: Between 1.00% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

